Keyphrases
Phase II Trial
100%
Metastatic Breast Cancer
100%
Temsirolimus
100%
PIK3CA mutation
100%
Tumor
60%
Breast Cancer
60%
Estrogen Receptor
40%
Stable Disease
40%
Tumor Samples
20%
Progression-free Survival
20%
PIK3CA
20%
Mammalian Target of Rapamycin (mTOR)
20%
Primary Tumor
20%
Human Epidermal Growth Factor Receptor 2 (HER2)
20%
Mutational Analysis
20%
Phase II Study
20%
Immunohistochemical Staining
20%
Disease-causing mutations
20%
Clinical Benefit
20%
Mutation Analysis
20%
AKT1
20%
Objective Response
20%
Heavily Pretreated
20%
Formalin-fixed Paraffin-embedded Tissue
20%
Immunohistochemical Markers
20%
Immunohistochemical Evaluation
20%
Mammalian Target of Rapamycin Pathway
20%
Activating mutation
20%
AKT/mammalian Target of Rapamycin
20%
Nuclear Staining
20%
Pathway mutation
20%
Rapamycin Analogs
20%
PIK3CA Gene
20%
Medicine and Dentistry
Neoplasm
100%
Metastatic Breast Cancer
100%
Temsirolimus
100%
Phase II Trials
100%
Breast Cancer
75%
Estrogen Receptor
50%
Mechanistic Target of Rapamycin
50%
Diseases
50%
Arm
25%
Progression Free Survival
25%
Primary Tumor
25%
Mutational Analysis
25%
Rapamycin
25%
Formaldehyde
25%
Protein Kinase B
25%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Phase II Trials
100%
Metastatic Breast Cancer
100%
Temsirolimus
100%
Breast Cancer
75%
Estrogen Receptor
50%
Mammalian Target of Rapamycin
50%
Diseases
50%
Progression Free Survival
25%
Primary Tumor
25%
Rapamycin
25%
Formaldehyde
25%
Protein Kinase B
25%